Key trends impacting Japan partnering

Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies. Doing deals is never easy, no matter the geography. However, it does seem that negotiating with Japanese companies...

Helping to Ensure Success After the Deal

One of my favorite places to hang out in Tokyo is the Apple Store in the Ginza area.  It is a beautiful four-story venue, complete with a theater (where one can sit and receive non-stop sessions on all of Apple’s products) and, of course, the Genius Bar.  One of the...

Japan Licensing Deals: A look back at 2016, and what to expect in 2017

On December 8th in Tokyo, Locust Walk hosted the 2nd annual “Locust Walk Japan Deal of the Year Award” event. We founded this event, which is co-sponsored by Clarivate Analytics (formerly Thomson Reuters), to celebrate the deals consummated throughout the year by...

New Horizons of the Regenerative Medicine Space in Japan

Exciting things are happening in Japan in the regenerative medicine space. As people who work in the industry may be aware, in 2014 Japan modified the regulations pertaining to regenerative medicine products through the adoption of the “Pharmaceutical and...

The Improving Japanese Pharmaceutical Regulatory Environment

There are new concerns arising in Japan around drug pricing. Last April, the Japanese government introduced a re-pricing rule for “huge seller drugs” and proceeded to slash the reimbursement price for Gilead’s Solvaldi by a hefty 30%. The concern now among industry...